References
- Portela A , EstellerM. Epigenetic modifications and human disease. Nat. Biotechnol.28 , 1057–1068 (2010).
- Kelly TK , De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat. Biotechnol.28(10) , 1069–1078 (2010).
- Almeida MI , ReisRM, CalinGA. MicroRNA history: discovery, recent applications, and next frontiers. Mutat. Res. doi:10.1016/j.mrfmmm.2011.03.009 (2011) (Epub ahead of print).
- Garzon R , MarcucciG, CroceCM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov.9(10) , 775–789 (2010).
- Green ED , Guyer MS; National Human Genome Research Institute. Charting a course for genomic medicine from base pairs to bedside. Nature470(7333) , 204–213 (2011).
- Dulbecco R . A turning point in cancer research: sequencing the human genome. Science231 , 1055–1056 (1986).
- Lander ES , LintonLM, BirrenB et al.; International Human Genome Sequencing Consortium: initial sequencing and analysis of the human genome. Nature409 , 860–921 (2001).
- Venter JC , AdamsMD, MyersEW et al. The sequence of the human genome. Science 291 , 1304–1351 (2001).
- Marshall E . Human genome 10th anniversary. Waiting for the revolution. Science331(6017) , 526–529 (2011).
- Wadman M . Fifty genome sequences reveal breast cancer‘s complexity. Nature doi:10.1038/news.2011.203 (2011) (Epub ahead of print).
- Blaxter M . Genetics. Revealing the dark matter of the genome. Science330(6012) , 1758–1759 (2010).
- Ashworth A , LordCJ, Reis-FilhoJS. Genetic interactions in cancer progression and treatment. Cell145(1) , 30–38 (2011).
- Hanahan D , WeinbergRA. Hallmarks of cancer: the next generation. Cell144(5) , 646–674 (2011).
- Haber DA , GrayNS, BaselgaJ. The evolving war on cancer. Cell145(1) , 19–24 (2011).
- Perry AS , WatsonRW, LawlerM, HollywoodD. The epigenome as a therapeutic target in prostate cancer. Nat. Rev. Urol.7(12) , 668–680 (2010).
- Egger G , LiangG, AparicioA, JonesPA. Epigenetics in human disease and prospects for epigenetic therapy. Nature429 , 457–463 (2004).
- Chi P , AllisCD, WangGG. Covalent histone modifications – miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer10(7) , 457–469 (2010).
- Sharma S , KellyTK, JonesPA. Epigenetics in cancer. Carcinogenesis31 , 27–36 (2010).
- Lane AA , ChabnerBA. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol.27 , 5459–5468 (2009).
- Belinsky SA , GrimesMJ, PicchiMA, et al. Combination therapy with Vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model. Cancer Res.71(2) , 454–462 (2011).
- Kaiser J . Epigenetic drugs take on cancer. Science330(6004) , 576–578 (2010).
- Munker R , CalinGA. MicroRNA profiling in cancer. Clin. Sci. (Lond).121(4) , 141–158 (2011).
- Morin RD , Mendez-LagoM, MungallAJ et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476(7360) , 298–303 (2011).
- Beltrao P , CagneyG, KroganN. Quantitative genetic interactions reveal biological modularity. Cell141(5) , 739–745 (2010).
- Davis DA , ChawlaNV. Exploring and exploiting disease interactions from multi-relational gene and phenotype networks. PLoS ONE6(7) , e22670 (2011).
Website
- miRBase. www.mirbase.org